Lv31
278 积分 2024-01-18 加入
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)
2小时前
已完结
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
3个月前
已完结
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
3个月前
已完结
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
3个月前
已完结
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
3个月前
已完结
Testicular germ-cell cancer
3个月前
已完结
CGCG clinical practice guidelines for the management of adult diffuse gliomas
3个月前
已完结
Targeted therapies for Glioblastoma multiforme (GBM): State‐of‐the‐art and future prospects
3个月前
已完结
Platinum-refractory germ cell tumors: an update on current treatment options and developments
3个月前
已完结
皖公网安备34019202002308
